Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product…
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi companyKER-0193, a novel, orally bioavailable…